The results of the DESTINY-04 trial presented at ASCO 2022 were received with a standing ovation.
The DESTINY 04 clinical trial looked whether the drug called trastuzumab deruxtecan (Enhertu or T-DXd) helps people with metastatic breast cancer. Enhertu is a type of targeted therapy that was developed to treat HER2-positive breast cancer. HER2 is a protein found on all breast cells. It controls how the cells grow and divide. When breast cells have too much HER2, cells can multiply too quickly. Growth may then become uncontrolled and lead to cancer.Previous results showed that Enhertu can benefit people with HER2-positive breast cancer. But what about HER2-negative breast cancer? Conventional thinking might suggest that an anti-HER2 drug would not work for cancers that are HER2-negative.
Surprisingly however, people whose cancer was previously labeled as HER2-negative – but who actually had very low levels of HER2– had better outcomes when they took Enhertu than those who received standard chemotherapy. These results challenge prior thinking that cancers are either HER2-positive or HER2-negative. Instead, some cancers may be reclassified to a third possible category called HER2-low. This may affect some people whose cancer was previously call triple-negative breast cancer (TNBC), a type of cancer that is often more aggressive and can have worse outcomes than other types. This offers a new treatment option for many people with hard-to-treat metastatic breast cancers and is likely to be a practice-changing information.
Read more about this new metastatic breast cancer treatment in FORCE’s review.
Patient Advocate Faces Thyroid Cancer Decades After Surviving Breast Cancer
September 5th 2023‘I feel like I've gone to continuing education classes as an advocate through reentering the health system in the cancer space,’ FORCE executive director and founder Sue Friedman, a breast cancer survivor who recently received a diagnosis of thyroid cancer, tells CURE.
Read More
Stepping Up Again for Hereditary Cancer Prevention
February 25th 2023On Feb. 6, HB 2783 was introduced into the Arizona House. Hopefully this bill will help address some of the issues surrounding genetic testing, genetic counseling, and insurance coverage for those who might be at risk for hereditary cancer. My wife died of a cancer that was totally preventable. Nobody should die of a preventable cancer.
Read More